Methylprednisolone for Heart Surgery in Infants - A Randomized, Controlled Trial.
Kevin D HillPrince J KannankerilJeffrey P JacobsH Scott BaldwinMarshall L JacobsSean M O'BrienDavid P BichelEric M GrahamBrian BlasioleAshraf ResheidatAdil S HusainSubramanyan Ram KumarJerry L KirchnerDianne S GallupJoseph W TurekMark BleiweisBret MettlerAlexis BenscoterEric WaldTara KaramlouAndrew H Van BergenDavid OvermanPirooz EghtesadyRyan ButtsJohn S KimJohn P ScottBrett R AndersonMichael F SwartzPatrick I McConnellDavid F VenerJennifer S Linull nullPublished in: The New England journal of medicine (2022)
Among infants undergoing surgery with cardiopulmonary bypass, prophylactic use of methylprednisolone did not significantly reduce the likelihood of a worse outcome in an adjusted analysis and was associated with postoperative development of hyperglycemia warranting insulin in a higher percentage of infants than placebo. (Funded by the National Center for Advancing Translational Sciences and others; STRESS ClinicalTrials.gov number, NCT03229538.).
Keyphrases
- minimally invasive
- coronary artery bypass
- high dose
- type diabetes
- surgical site infection
- patients undergoing
- randomized controlled trial
- atrial fibrillation
- insulin resistance
- percutaneous coronary intervention
- adipose tissue
- acute coronary syndrome
- double blind
- coronary artery disease
- glycemic control
- diabetic rats
- study protocol